ACB vs. CDXC, BTMD, MDWD, FTLF, MNMD, USNA, CGC, CRON, AMRN, and ADCT
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include ChromaDex (CDXC), biote (BTMD), MediWound (MDWD), FitLife Brands (FTLF), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Canopy Growth (CGC), Cronos Group (CRON), Amarin (AMRN), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.
Aurora Cannabis (NASDAQ:ACB) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk.
ChromaDex has a consensus price target of $6.00, indicating a potential upside of 72.41%. Given ChromaDex's higher possible upside, analysts clearly believe ChromaDex is more favorable than Aurora Cannabis.
ChromaDex received 152 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 63.99% of users gave ChromaDex an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
Aurora Cannabis has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
In the previous week, ChromaDex had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 17 mentions for ChromaDex and 12 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 1.13 beat ChromaDex's score of 0.24 indicating that Aurora Cannabis is being referred to more favorably in the media.
ChromaDex has a net margin of -4.24% compared to Aurora Cannabis' net margin of -48.82%. ChromaDex's return on equity of -12.61% beat Aurora Cannabis' return on equity.
ChromaDex has lower revenue, but higher earnings than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 15.4% of ChromaDex shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 10.6% of ChromaDex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
ChromaDex beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
